Amino-terminally truncated rantes as chemokine antagonists
AssigneeApplied Research Systems ARS Holding N.V.
InventorsPaul Proost, Sofie Struyf, Jo Van Damme
Life of this patent
Estimating the term…
Abstract
The present invention relates to amino-terminally truncated RANTES, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
Claims14
Amino-terminally truncated RANTES, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES and having chemokine antagonistic activity.
Amino-terminally truncated RANTES, according to one or more of the preceding claims, in a glycosylated form.
DNA molecules comprising the DNA sequences coding for the amino-terminally truncated RANTES of the invention according to one or more of the preceding claims, including nucleotide sequences substantially the same.
A protein according to any of the claims from 1 to 4 for use as medicament.
Use of a protein according to any of the claims from 1 to 4, in the manufacture of a medicament for the therapy and/or diagnosis of diseases, in which an antagonistic activity of the chemokine effects is required.
A pharmaceutical composition comprising the protein according to any of the claims from 1 to 4 together with one or more pharmaceutically acceptable carriers and/or excipients.
Use of CD26/DPP IV in the therapy and/or diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required.
Dependencies are inferred from the claim text.